EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Revance Therapeutics's enterprise value is $545.5 Mil.
Revance Therapeutics's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was $236.6 Mil. Therefore, Revance Therapeutics's EV-to-Revenue for today is 2.31.
The historical rank and industry rank for Revance Therapeutics's EV-to-Revenue or its related term are showing as below:
RVNC'
s EV-to-Revenue Range Over the Past 10 Years
Min: 2.13 Med: 414.75 Max: 5598.45
Current: 2.31
During the past 13 years, the highest EV-to-Revenue of Revance Therapeutics was 5598.45. The lowest was 2.13. And the median was 414.75.
RVNC's EV-to-Revenue is ranked better than 77.82% of 1037
companies
in the Biotechnology industry
Industry Median: 7.95
vs RVNC: 2.31
Revance Therapeutics EV-to-Revenue Historical Data
The historical data trend for Revance Therapeutics's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Revance Therapeutics's EV-to-Revenue
For the Biotechnology subindustry, Revance Therapeutics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Revance Therapeutics's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Revance Therapeutics's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Revance Therapeutics's EV-to-Revenue falls into.
Revance Therapeutics's current Enterprise Value is $545.5 Mil.
Revance Therapeutics's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $236.6 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Revance Therapeutics's share price for today is $3.48.
Revance Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.72.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Revance Therapeutics EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Revance Therapeutics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Revance Therapeutics (Revance Therapeutics) Business Description
Revance Therapeutics Inc is a biotechnology company focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The company has launched a prestige aesthetics portfolio, which includes the RHA Collection of dermal fillers and the HintMD platform. Its main products include DaxibotulinumtoxinA for Injection and DaxibotulinumtoxinA for Injection Aesthetics. The operating business segments are the Product and the Service Segment. The Products segment generates maximum revenue and is engaged in the research and development of aesthetic and therapeutic products.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
RVNC has been successfully added to your 